CRP-Guided Testing Cuts Antibiotic Use in COPD Exacerbations
Lower percentage of patients reported antibiotic use, received antibiotic prescriptions
Bacterial Infections
WHO Updates List of Essential Medicines
The World Health Organization (WHO) has updated the WHO Model List of Essential Medicines for 2019.
Inhaled Gallium Citrate Gets Orphan Drug Designation for Lung Infection Tx in Cystic Fibrosis
AR-501, an inhaled formulation of gallium citrate, is a small molecule anti-infective with broad spectrum activity against Gram-negative and Gram-positive bacteria in vitro, including antibiotic-resistant strains.
Do Statins Protect Against C. difficile Infection Development?
Findings of a recently published systematic review revealed that statins may protect against Clostridium difficile infection (CDI) development as well as improve the success of treatment. To investigate the association between these lipid-lowering agents and CDI, study authors searched MEDLINE to obtain clinical studies evaluating the effects of statins on CDI-related outcomes (ie, CDI development,…
Rotavirus Vaccine Led to Reduced Disease Prevalence, Season Duration
In postvaccine period, a biennial pattern emerged with alternating years of high, low disease activity
Emerging Tickborne Illnesses: Beyond Lyme Disease
Although most providers are familiar with the symptoms of Lyme disease, coinfection with other tickborne illnesses such as babesiosis, human granulocytic anaplasmosis, and human monocytic ehrlichiosis is possible and becoming more prevalent.
2018-2019 Influenza Season in US Longest in 10 Years
Season was of moderate severity and lasted 21 weeks; illness mainly attributed to influenza A viruses
ANI’s Vancomycin Hydrochloride for Oral Solution Gets FDA Approval
Vancomycin is indicated to treat enterocolitis caused by Staphylococcus aureus and antibiotic-associated pseudomembranous colitis caused by C. difficile.
Baxdela Gets FDA’s Priority Review for Community-Acquired Bacterial Pneumonia
The sNDA is supported by data from the phase 3, double blind, DEFINE-CABP trial (N=860) which compared the safety and efficacy of Baxdela to moxifloxacin for the treatment of CABP.
PPI Use for Up to Three Years Safe During Anticoagulant Tx
Safety profile did not differ for pantoprazole versus placebo except greater risk for enteric infections
